内页大图
Home > News > News
Recurrent mantle cell lymphoma can be effectively treated with CAR-T cell therapy

Recurrent mantle cell lymphoma can be effectively treated with CAR-T cell therapy

A one-year follow-up led by the University of Texas MD Anderson Cancer Center found that most patients with mantle cell lymphoma (mantle cell lymphoma) who are resistant to previous treatments can benefit from chimerism that targets CD19 antigen...

2020-09-30
Elucidating the mechanism of T cell depletion is expected to improve cancer immunotherapy

Elucidating the mechanism of T cell depletion is expected to improve cancer immunotherapy

In the latest research report published in the international journal “Immunity”, scientists at Emory University have studied the “depleted” immune cells caused by chronic viral infections to provide information on how to improve cancer immunotherapy ...

2020-09-30
How to use CRISPR gene editing technology to improve human white blood cells and effectively fight cancer?

How to use CRISPR gene editing technology to improve human white blood cells and effectively fight cancer?

A few days ago, in the United States, researchers used gene editing tools to treat three patients with advanced cancer for the first time. At the same time, the results of the phase 1 clinical trial showed high expectations...

2020-09-30
Use convertible CAR-T cells to attack potential HIV

Use convertible CAR-T cells to attack potential HIV

Researchers from the Gladstone Institute of Virology and Immunology and other scientific institutes have used transformable CAR-T cells to attack potential HIV and established indications...

2020-09-30
Mesenchymal stem cell transplantation is expected to treat gastric ulcers caused by non-steroidal anti-inflammatory drugs

Mesenchymal stem cell transplantation is expected to treat gastric ulcers caused by non-steroidal anti-inflammatory drugs

In high-income countries, non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most important causes of peptic ulcer disease...

2020-09-30
DNA damage may re-regulate cancer gene regulatory mechanisms

DNA damage may re-regulate cancer gene regulatory mechanisms

Understanding the mechanisms that mediate extensive DNA damage in cancer genomes has always been the most interesting research area for cancer researchers...

2020-09-30
Combined immunotherapy can significantly improve the long-term survival of patients with melanoma

Combined immunotherapy can significantly improve the long-term survival of patients with melanoma

According to a study by the Royal MarsdenHS Foundation, the combination of two immunotherapeutics (ipilimumab and nivolumab) can prevent or reverse the progression of advanced melanoma within 5 years...

2020-09-30
Expected to develop new therapies for drug-resistant cancer cells

Expected to develop new therapies for drug-resistant cancer cells

In the latest research report published in the international journal Molecular Cell, scientists from Trinity College Dublin and other institutions have explored many new biological targets by studying and understanding the internal network of genes r...

2020-09-30
Clinical trials show that hematopoietic stem cell transplantation can reverse neuromyelitis optica

Clinical trials show that hematopoietic stem cell transplantation can reverse neuromyelitis optica

In a new clinical study, researchers at Northwestern University’s Fernberg School of Medicine and May York Clinic reported that hematopoietic stem cell transplantation can reverse a debilitating neurological disease called neuromyelitis optica (Neuro...

2020-09-30
iPSC-derived CAR-NK therapy has been clinically approved, which can solve the recurrence and cost challenges of CAR-T

iPSC-derived CAR-NK therapy has been clinically approved, which can solve the recurrence and cost challenges of CAR-T

Recently, Fate Therapeutics, which is committed to the development of cellular immunotherapy, announced that the US FDA has approved the investigational new drug (IND) application for its investigational therapy FT596...

2020-09-30
When tumor cells leave their original site and spread to other distant organs, most cancers are fatal (cancer metastasis)

When tumor cells leave their original site and spread to other distant organs, most cancers are fatal (cancer metastasis)

Target cells near tumor metastatic habitats are expected to develop new anti-cancer strategies...

2020-09-30
Reveal new secrets of NK cells and develop immunotherapy against cancer cells

Reveal new secrets of NK cells and develop immunotherapy against cancer cells

The natural killer (NK) cells of the immune system recognize and attack two main types of dangerous cells: virus-infected cells and cancer-affected cells...

2020-09-30
How to accurately target bladder cancer with common cold virus?

How to accurately target bladder cancer with common cold virus?

Non-muscle invasive bladder cancer is the tenth most common cancer in the UK and is difficult to treat. Current treatments are invasive and often have unpleasant side effects. The cancer also has a high recurrence rate-usually in a more aggressive fo...

2020-09-30
New lipid signaling targets may improve T cell immunotherapy

New lipid signaling targets may improve T cell immunotherapy

The immune system monitors our body, looking for things that do not belong to us, such as bacteria and viruses...

2020-09-30
Potential to use stem cells to treat myocardial infarction

Potential to use stem cells to treat myocardial infarction

As an emergency medical event caused by severe cardiovascular disease, myocardial infarction (MI) causes permanent life-threatening damage to the heart...

2020-09-30
By targeting the carrier protein E, it is expected to completely eliminate the hepatitis B virus in the human body

By targeting the carrier protein E, it is expected to completely eliminate the hepatitis B virus in the human body

Recently, scientists at the University of Alabama in the United States have discovered through research that human apolipoprotein E (apolipoprotein E) may promote hepatitis B virus infection and production...

2020-09-30